Martin Ian, Kim Jungwoo Wren, Dawson Valina L, Dawson Ted M
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Neurochem. 2016 Oct;139 Suppl 1:75-76. doi: 10.1111/jnc.13549. Epub 2016 Feb 22.
A common cause of Parkinson disease are missense mutations in the leucine-rich repeat kinase 2 (LRRK2) catalytic Roc-COR domain, leading to a decrease in GTPase activity; and its kinase domain, leading to an increase in kinase activity and subsequent LRRK2 toxicity. Targeting LRRK2 with selective, brain-permeable kinase inhibitors is a promising approach to reduce toxicity, and thus is a major goal of clinical development. Understanding the specific signaling cascades triggered by LRRK2 mutations will be key to this aim. This article is part of a special issue on Parkinson disease.
帕金森病的一个常见病因是富含亮氨酸重复序列激酶2(LRRK2)催化性Roc-COR结构域中的错义突变,导致GTP酶活性降低;以及其激酶结构域中的错义突变,导致激酶活性增加及随后的LRRK2毒性。用具有脑渗透性的选择性激酶抑制剂靶向LRRK2是一种有望降低毒性的方法,因此是临床开发的一个主要目标。了解由LRRK2突变触发的特定信号级联反应将是实现这一目标的关键。本文是关于帕金森病的一期特刊的一部分。